Search Result

Results for "

NASH fibrosis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	17β-HSD (3) Caspase (1) CCR (2) Cytochrome P450 (2) Dipeptidyl Peptidase (1) FABP (1) FXR (5) GCGR (2) GLP Receptor (1) GPR119 (1) Integrin (1) Mitochondrial Metabolism (1) NF-κB (1) NOD-like Receptor (NLR) (2) Phosphatase (1) PPAR (2) TAM Receptor (1) TGF-beta/Smad (1)
By Research Areas:	Cancer (1) Inflammation/Immunology (12) Metabolic Disease (13) Neurological Disease (3)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Targets Recommended: CFTR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-151481

FXR antagonist 1	FXR	Metabolic Disease
FXR antagonist 1 (compound F6) is an orally active and selective intestinal FXR antagonist (IC₅₀=2.1 μM). FXR antagonist 1 selectively inhibits intestinal FXR signalling through antagonism of intestinal FXR and feedback activation of hepatic FXR to improve hepatic steatosis, inflammation and fibrosis in NASH (nonalcoholic steatohepatitis) models. FXR antagonist 1 can be used in NASH studies .

HY-153114

HEC96719	FXR	Inflammation/Immunology
HEC96719 is a selective and orally active tricyclic farnesoid X receptor (FXR) agonist with EC₅₀ values of 1.37 and 1.55 nM by time-resolved fluorescence energy transfer (TR-FRET) and luciferase reporter assays, respectively. HEC96719 significantly improves non-alcoholic steatohepatitis (NASH) and liver fibrosis with favorable tissue distribution in liver and intestine. HEC96719 can be used for the research of non-alcoholic steatohepatitis .

HY-151932

FXR agonist 3	FXR	Inflammation/Immunology
FXR agonist 3 is an anti-NASH agent, acting by activating FXR. FXR agonist 3 inhibits COL1A1, TGF-β1, α-SMA and TIMP1 expression with anti-fibrogenic activity. FXR agonist 3 significantly reduces liver steatosis and inflammation, improves liver fibrosis level .

HY-119039

RU-301 1 Publications Verification	TAM Receptor	Inflammation/Immunology Cancer
RU-301 is a pan TAM inhibitor that blocks Gas6-induced TAM activation and tumorigenicity. RU-301 significantly reduces nonalcoholic steatohepatitis (NASH) fibrosis, along with attenuates ERK activation and TGFβ1 expression. RU-301 can be used in studies of cancer and nonalcoholic steatohepatitis .

HY-16521

VX-166	Caspase	Inflammation/Immunology
VX-166, a pan caspase inhibitor, can be used for the research of Non- Alcoholic Fatty Liver Disease (NAFLD), nonalcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), and other diseases involving fibrosis, steatosis, or inflammation of the liver .

HY-150787

BMS-986339	FXR Cytochrome P450	Metabolic Disease
BMS-986339 is an orally active, potent FXR agonist. BMS-986339 forms H-bond with His298 and ASN287 residues. BMS-986339 can be used in the research of primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH), anti-fibrosis .

HY-163498

NLRP3-IN-37	NOD-like Receptor (NLR)	Neurological Disease Inflammation/Immunology
NLRP3-IN-37 (Compound 23) is a NLRP3 inhibitor (EC₅₀: 5 nM). NLRP3-IN-37 can be used for NLRP3 related research, such as gout, pseudogout, CAPS, NASH fibrosis, heart failure, idiophathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease and traumatic brain injury .

HY-172105

Anti-NASH agent 2	PPAR	Metabolic Disease Inflammation/Immunology
Anti-NASH agent 2 (compound 21) is an inhibitor of de novo adipogenesis activity and α-SMA gene expression. Anti-NASH agent 2 improves hepatic steatosis, edema, inflammatory infiltrates, and liver fibrosis in NASH mouse models .

HY-P6177

SGP8	Dipeptidyl Peptidase	Inflammation/Immunology
SGP8 (IAVPGEVA) is an octapeptide produced by hydrolysis of soybean 11S globulin, which has the effects of regulating lipid metabolism, inflammation and fibrosis. SGP8 (IAVPGEVA) exhibits inhibitory activity against DPP4 and inhibits the JNK-c-Jun signaling pathway, and has the ability to inhibit non-alcoholic steatohepatitis (NASH) .

HY-128145

HSD17B13-IN-41	17β-HSD	Metabolic Disease
HSD17B13-IN-41 (Compound C) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-41 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH .

HY-157664

HSD17B13-IN-38	17β-HSD	Metabolic Disease
HSD17B13-IN-38 (Compound D) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-38 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH .

HY-157665

HSD17B13-IN-39	17β-HSD	Metabolic Disease
HSD17B13-IN-39 (Compound A) is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). HSD17B13-IN-39 can be used for research on liver diseases, metabolic diseases, or cardiovascular diseases, such as NAFLD or NASH .

HY-158127

FABP1-IN-1 1 Publications Verification	FABP	Metabolic Disease Inflammation/Immunology
FABP1-IN-1 (44) is a selective FABP1 inhibitor, with an IC₅₀ of 4.46 μM. FABP1-IN-1 (44) can be used for the research of NASH .

HY-108022

Azemiglitazone MSDC-0602	Mitochondrial Metabolism PPAR	Neurological Disease Metabolic Disease Inflammation/Immunology
Azemiglitazone (MSDC-0602) is an orally active thiazolidinedione (TZD) -like molecule, which binds to PPARγ with low binding and activating affinity. Azemiglitazone inhibits mitochondrial pyruvate carrier (MPC), which inhibits Alzheimer’s disease and diminishes nonalcoholic steatohepatitis (NASH) caused liver injury .

HY-W011121

2-Oleoylglycerol 2-OG	GPR119 NF-κB TGF-beta/Smad GLP Receptor	Metabolic Disease
2-Oleoylglycerol (2-OG) is a lipid found in the diet. It is a GPR119 agonist, with an EC₅₀ value of 2.5 μM in activating hGPR119 in transiently transfected COS-7 cells. 2-Oleoylglycerol enhances the inflammatory response of macrophages and promotes fibrosis by activating the GPR119/TAK1/NF-κB/TGF-β1 signaling pathway. It also stimulates glucagon-like peptide 1 (GLP-1) secretion in vivo. 2-Oleoylglycerol is expected to be used in the research of non-alcoholic steatohepatitis (NASH) .

HY-P2231A

Cotadutide acetate 1 Publications Verification MEDI0382 acetate	GCGR	Metabolic Disease
Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .

HY-P2231

Cotadutide 1 Publications Verification MEDI0382	GCGR	Metabolic Disease
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC₅₀ values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .

HY-117621

PF-04634817	CCR	Metabolic Disease
PF-0463481 is a potent and orally active dual CCR2/CCR5 antagonist with comparable human and rodent CCR2 potency (rat IC₅₀=20.8 nM), and displays 10-20 fold less rodent CCR5 potency (rat IC₅₀=470 nM). PF-0463481 is safe and well-tolerated and has the potential for the study of diabetic nephropathy .

HY-117621A

PF-04634817 succinate	CCR	Metabolic Disease
PF-0463481 succinate is a potent and orally active dual CCR2/CCR5 antagonist with comparable human and rodent CCR2 potency (rat IC₅₀=20.8 nM), and displays 10-20 fold less rodent CCR5 potency (rat IC₅₀=470 nM). PF-0463481 succinate is safe and well-tolerated and has the potential for the study of diabetic nephropathy .

HY-47888

PLN-1474	Integrin	Inflammation/Immunology
PLN-1474 (compound 1) is an orally active and selective ανβ1 integrin inhibitor with an IC50 value of <50 nM. PLN-1474 reduces levels of pSMAD3/SMAD3 in liver, hepatic collagen gene expression and hepatic OHP concentration in liver fibrosis mouse model. PLN-1474 can be used for the research of preventing, delaying or researching a fibrotic or cirrhotic disease or disorder.

HY-163497

NLRP3-IN-38	NOD-like Receptor (NLR)	Neurological Disease Inflammation/Immunology
NLRP3-IN-38 (Compound 18) is an inhibitor for NOD-like receptor protein 3 (NLRP3), that inhibits NLRP3 inflammasome activation with an EC₅₀ of 23 nM .

HY-134988

EDP-305	FXR Phosphatase Cytochrome P450	Inflammation/Immunology
EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC₅₀ values of 34 nM (chimeric FXR in CHO cells) and 8 nM (full-length FXR in HEK cells). EDP-305 shows a potent and consistent antifibrotic effect. EDP-305 can be used for primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) research .

Cat. No.	Product Name

HY-L199

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library	3,542 compounds
Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is the primary liver manifestation of metabolic syndrome. The growth of NAFLD has coincided with the obesity epidemic. NAFLD is composed of excess lipid accumulation in the liver, causing steatotoxicity, and shows a wide range of histopathological abnormalities. NAFLD may progress from simple steatosis to Non-alcoholic steatohepatitis (NASH) with or without fibrosis (NASH), and eventually to cirrhosis and hepatocellular carcinoma. To date, very few drugs have been approved for marketing specifically for the treatment of NAFLD, so increased efforts to develop NAFLD drugs are necessary. MCE designs a unique collection of 3,542 small molecules with definite or potential anti-NAFLD activity, which is an important tool for studying the pathological mechanism of NAFLD and developing drugs for NAFLD.

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

3,542 compounds

Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is the primary liver manifestation of metabolic syndrome. The growth of NAFLD has coincided with the obesity epidemic. NAFLD is composed of excess lipid accumulation in the liver, causing steatotoxicity, and shows a wide range of histopathological abnormalities. NAFLD may progress from simple steatosis to Non-alcoholic steatohepatitis (NASH) with or without fibrosis (NASH), and eventually to cirrhosis and hepatocellular carcinoma. To date, very few drugs have been approved for marketing specifically for the treatment of NAFLD, so increased efforts to develop NAFLD drugs are necessary.

MCE designs a unique collection of 3,542 small molecules with definite or potential anti-NAFLD activity, which is an important tool for studying the pathological mechanism of NAFLD and developing drugs for NAFLD.

Cat. No.	Product Name	Target	Research Area